Company Overview of Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals, Inc., a development stage pharmaceutical company, is engaged in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. The company’s product portfolio includes ORMD0801, an oral insulin capsule that is in Phase II clinical trials for the treatment of diabetes; and ORMD0901, an analog for GLP-1 gastrointestinal hormone, which is in pre-clinical trials. Its portfolio of product candidates is based on intellectual property that allows for the protection of proteins and polypeptides in the stomach, and for their absorption through the gastrointestinal wall. The company was formerly known as...
Hi-Tech Park 2/4
PO Box 39098
Founded in 2002
Key Executives for Oramed Pharmaceuticals Inc.
Chief Executive Officer
Total Annual Compensation: $259.7K
Chief Financial Officer
Total Annual Compensation: $98.4K
Chief Operating Officer and Vice President of Business Development
Total Annual Compensation: $48.4K
Chief Medical & Technology Officer and Director
Total Annual Compensation: $188.4K
Compensation as of Fiscal Year 2013.
Oramed Pharmaceuticals Inc. Key Developments
Intellectual Property Department of Hong Kong Grants Patent for Oral Administration of Insulin of Oramed
Apr 10 14
Oramed Pharmaceuticals Inc. announced that the Intellectual Property Department of Hong Kong has granted the company's patent for its invention, titled Methods and Compositions for Oral Administrations of Proteins.
Oramed Pharmaceuticals Inc. Presents at Barclays Capital 2014 Global Healthcare Conference, Mar-11-2014 08:30 AM
Mar 6 14
Oramed Pharmaceuticals Inc. Presents at Barclays Capital 2014 Global Healthcare Conference, Mar-11-2014 08:30 AM. Venue: Loews Miami Beach Hotel, Miami, Florida, United States. Speakers: Nadav Kidron, Chief Executive Officer, President and Executive Director.
Oramed Pharmaceuticals Inc. to Present Results from its Phase 2a FDA trial on ORMD-0801
Mar 3 14
Oramed Pharmaceuticals Inc. announced that it will be presenting detailed results from its recently completed Phase 2a FDA trial on ORMD-0801, its orally ingestible insulin capsule at the 2014 GTC Diabetes Summit taking place from April 23-25, 2014, in Boston, Massachusetts, USA. This was a randomized, double-blind, placebo-controlled Phase 2a study designed to assess the safety and tolerability of multiple bedtime doses of the ORMD-0801 oral insulin formulation in adult Type 2 diabetes patients inadequately controlled with diet alone or diet and metformin. Preliminary results were announced by the company on January 30(th) of this year.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|